Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K7IW
|
||||
| Former ID |
DIB019207
|
||||
| Drug Name |
compound 11d
|
||||
| Drug Type |
Small molecular drug
|
||||
| Formula |
C23H25N3O5
|
||||
| InChI |
InChI=1S/C23H25N3O5/c1-29-19-4-6-21-16(10-19)9-17(14-31-21)23(28)26-20-5-3-15(18-12-24-25-13-18)11-22(20)30-8-2-7-27/h3-6,10-13,17,27H,2,7-9,14H2,1H3,(H,24,25)(H,26,28)/t17-/m0/s1
|
||||
| InChIKey |
YHIPVWFQESXDIE-KRWDZBQOSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Rho associated protein kinase 2 | Target Info | Inhibitor | [543434] | |
| CDC42 binding protein kinase alpha (DMPK-like) | Target Info | Inhibitor | [543436] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Chemokine signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Wnt signaling pathway | |||||
| Axon guidance | |||||
| Focal adhesion | |||||
| Platelet activation | |||||
| Leukocyte transendothelial migration | |||||
| Regulation of actin cytoskeleton | |||||
| Oxytocin signaling pathway | |||||
| Pathogenic Escherichia coli infection | |||||
| Shigellosis | |||||
| Salmonella infection | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| PANTHER Pathway | Cytoskeletal regulation by Rho GTPase | ||||
| WikiPathways | G13 Signaling Pathway | ||||
| Regulation of Actin Cytoskeleton | |||||
| Focal Adhesion | |||||
| JAK/STAT | |||||
| Spinal Cord Injury | |||||
| Pathogenic Escherichia coli infection | |||||
| Leptin signaling pathway | |||||
| Semaphorin interactions | |||||
| Integrin-mediated Cell Adhesion | |||||
| GPCR downstream signaling | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| Androgen receptor signaling pathway | |||||
| References | |||||
| Ref 542990 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8197). | ||||
| Ref 552148 | Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors. Med. Chem. Commun., 2011,2, 73-75. | ||||
| Ref 543434 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504). | ||||
| Ref 543436 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1507). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.